abc biopply ag
abc biopply realized early on that the expertise required to efficiently use organoid-based disease models far exceeds the competences of an ordinary cell culture laboratory. The underestimation of the complexity of 3D cell culture often leads to poor validation, a lack of standardization, and limited predictive power of the results. abc biopply therefore offers a distinctive organoid servicing and licensing model based on its proprietary 3D CoSeedis Multi-Organoid in chip technology™, delivering validated and standardized results. The company aims to become an “animal-free Charles River” by establishing Organoid Competence Centers in different parts of the world. Our proprietary technology creates hundreds of miniature versions of patient organs in a laboratory setting, using both healthy and diseased tissues. Thus, our innovative technology bridge the gap in predictability between the lab and patients response. Since our establishment in 2018, we have collaborated with numerous clients, developing customized assays, standardize and validate our 3D technology platform to establish IND relevance.
Shanghai HepaBiotech
Shanghai HepaBiotech is dedicated to the development and application of advanced 3D microtissue platforms, delivering robust safety, efficacy, and metabolic evaluations to support preclinical drug development. Our founding team originates from the Karolinska Institute, home to the Nobel Assembly for the Nobel Prize in Physiology or Medicine. We have partnered with more than sixty leading pharmaceutical companies worldwide, providing industry-trusted preclinical evaluation solutions that accelerate innovative drug development.
Luna LifeSci Advisors
Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
Frontier Bio Corporation
Frontier Bio creates bioprinted 3D human models (BBB, lung, vasculature) to improve clinical translation and reduce reliance on animal testing.
innoVitro
As a CRO, innoVitro specializes in human-cell analytics for drug safety, toxicity, and efficacy in preclinical cardiac risk assessment.
Nagi Bioscience
We are a Swiss high-tech company developing and offering cutting-edge biological testing solutions that enable scientists to generate insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our technologies are designed to integrate seamlessly into existing lab environments, enhancing efficiency, accuracy, and reproducibility.
Quris.AI
Quris.AI is transforming drug safety prediction by uniquely combining advanced AI capabilities with cutting edge 3D organ models, enabling predictions with unprecedented accuracy and scalability. our platform has been extensively validated by leading Pharma companies, including a long term collaboration with Merck GmbH. By predicting safety in human relevant 3D models, our platform significantly increases the likelihood of clinical success and reduces significantly the need for animal testing.
CanChip GmbH
We are a commercial provider of a microphysiological system either as a product or service.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.